Is red yeast rice dangerous? What the Kobayashi case shows

1. Two risks that should not be conflated

Red yeast rice is produced by cultivating a mold from the Monascus genus on rice. It may contain several monacolins, including monacolin K. This first level of risk comes from the product’s expected pharmacological action and potential interactions.

France’s ANSES notes that monacolin K has the pharmacological characteristics of statins and that amounts can vary widely. Of 25 well-documented French adverse-event reports, causality was considered likely or very likely in 12. The reports mainly involved muscle injury, along with three cases of liver injury with or without associated muscle injury. ANSES – risks of supplements based on red yeast rice

The Kobayashi case concerns a second risk: unexpected contamination during manufacturing. A compliant product can still be inappropriate for a particular person; conversely, a specific contamination event does not show that the entire category contains the same contaminant.

2. This supplement belongs at the very top of the pyramid

For most people who strength train, red yeast rice does not directly improve progression, muscle gain, or recovery. It should not become an automatic purchase simply because it is marketed as “natural” or associated with cholesterol.

The foundation remains a sustainable diet, an appropriate energy balance, enough protein, fiber, and micronutrients, regular activity, and a medical assessment of cardiovascular risk when warranted. This supplement belongs at the top of the pyramid, reserved for a specific and professionally supervised situation.

That does not mean every supplement is useless. Supplementation can address an identified need or genuine constraint. But red yeast rice should not replace prescribed cholesterol-lowering treatment: cardiovascular risk cannot be reduced to a single number for a capsule to manage without a diagnosis. Nalko guide – useful strength training supplements, ANSES — take advice before using red yeast rice

• Sustainable diet and habits.
• An appropriate energy balance and activity level.
• Protein, fiber, micronutrients and variety.
• Assessment of cardiovascular risk by a professional.
• A targeted supplement only when its role is justified.

3. The Kobayashi case timeline

According to Osaka’s final report, Kobayashi received its first health report on January 15, 2024. On March 22, the company announced that use of three products should stop and voluntarily recalled them. Japan’s Ministry of Health requested action under the Food Sanitation Act on March 26; Osaka issued the administrative recall order on March 27.

In September 2024, the ministry presented the contamination investigation’s findings. Osaka classified the incident as food poisoning on October 10 and published its final report on March 19, 2025. MHLW — timeline, order and investigation of Kobayashi, Osaka City — final report on the health investigation

The Osaka report notes the delay between the first health report and notification of the authorities. It concludes that escalating the issue after several similar cases could have limited its spread. That is a published administrative conclusion, not an assumption added by this article.

• January 15, 2024: first report received by the company according to Osaka.
• March 22: announcement of the voluntary recall.
• March 27: administrative order to recall three products.
• September 18: publication of the cause investigated by the ministry.
• October 10: Osaka classifies the incident as food poisoning.
• March 19, 2025: final city report.

4. What the investigation established about the contamination

Investigators identified Penicillium adametzioides, a mold different from the Monascus intentionally used for fermentation. The Japanese ministry indicates that the contamination occurred during fermentation and that this mold produced puberulic acid. MHLW — conclusion on contamination and puberulic acid

Animal studies found kidney injury with puberulic acid. The ministry concluded that the substance could cause renal dysfunction under the conditions studied, unlike the two other compounds analyzed, called Y and Z. This demonstrates experimental toxicity; it does not automatically establish causation in every human case. MHLW — experimental results on puberulic acid

The Osaka report also describes control weaknesses: mold risk was not adequately incorporated into the HACCP plan; documentation was incomplete; cracks or leaks were recorded on drums; internal escalation rules were imprecise; and traceability was not sufficiently formalized. The report presents several plausible pathways, not one handling error proven to have caused the entire problem. Osaka City — final report on food-safety control failures

5. The recall did not affect all red yeast rice

The administrative order related to three Kobayashi Pharmaceutical products: Beni-koji Choleste-Help, Naishi-Help Plus Cholesterol and Nattou-Kinaze SaraSara tablet GOLD. Other voluntary recalls related to certain raw materials have been published separately.

The ministry requested self-inspections from 52 direct raw material customers and 173 indirect customers. None declared a product meeting either of the two criteria examined by this survey. The authorities therefore did not generalize the order to the 225 companies. MHLW — products under order and chain controls

“All red yeast rice was contaminated” is false. So is “other products must be risk-free”: the absence of this acid does not eliminate the effects of monacolins, variation in composition, or interactions. Check the manufacturer, exact product, batch, dose, and medical context.

6. What is the precise legal status?

The record includes four distinct developments: the voluntary recall announced on March 22, 2024; the administrative order issued on March 27; a company-run compensation program; and a shareholder derivative lawsuit filed in 2025 against two serving directors and five former directors.

In the derivative lawsuit, the shareholder seeks approximately 13.55 billion yen from the seven directors on the company’s behalf, alleging breaches of their management duties. This is neither a consumer class action nor a judgment against the defendants. The official source announces the filing in an Osaka court but does not publish a final outcome. Kobayashi — official announcement of shareholder civil action

As of July 22, 2026, the official sources reviewed do not document a criminal conviction in this case. The cited official source establishes that a civil lawsuit was filed in April 2025, but does not publish a final outcome. On its own, it does not establish the lawsuit’s procedural status as of July 22, 2026. The accurate description is administrative action, a health investigation, and the filing of a civil lawsuit—not a company found criminally guilty.

7. Why large case counts do not establish causation on their own

As of July 20, 2026, Kobayashi reported 3,406 cumulative instances of seeking medical care—not necessarily 3,406 distinct people—including 617 cumulative hospitalizations. The company produced these totals; they include both kidney-related and non-kidney-related situations and do not, on their own, constitute an independent assessment of causation. Kobayashi — counter published as of July 20, 2026

The same company count recorded 428 inquiries linked to a death. Kobayashi said that non-use of the products had been confirmed in 273 of those inquiries; the remaining 155 were divided among reviews that were complete, ongoing, or impossible to pursue further. Kobayashi stated that it had identified no case in which use clearly caused the death.

The accurate wording is therefore “428 reports linked to a death, according to the company,” never “428 deaths caused.” It would be equally excessive to treat the company’s position as general proof that no fatal risk exists. The source, date, definition of the count, and limitations matter as much as the number.

8. A voluntary compensation program is not a court ruling

As of June 30, 2026, Kobayashi reported approximately 1,350 contacts and 900 applications received through its compensation program. About 510 people had been found eligible; 370 payments had been completed, and 140 claims remained under review or discussion. Kobayashi — progress of the compensation system

These figures describe a voluntary mechanism administered by the company. Eligibility or payment is not a judicial determination of causation in each case; rejection or an incomplete claim does not prove that no harm occurred.

When reading a health case, keep four categories separate: reported cases, assessed causation, administrative action, and court decisions. Sensational headlines often arise by collapsing them together.

9. What should you do after using an affected product?

Japan’s Ministry of Health says to stop using the three products covered by the order and seek medical advice for any symptoms or abnormalities. For any other product, check the manufacturer, full product name, batch, and official notices instead of relying only on the words “red yeast rice.” MHLW — stop-use advice and products covered

Keep the packaging, receipt, and batch number. Do not take the product again after an adverse reaction to test the response yourself. Tell the doctor or pharmacist about every supplement and medication taken at the same time.

ANSES advises against these supplements for people taking statins or who stopped a statin because of adverse effects. It also advises against use during pregnancy or breastfeeding; in children and adolescents; in people over 70; in people with certain kidney, muscle, thyroid, or liver conditions; and among people who consume large amounts of grapefruit or alcohol. Never stop prescribed cholesterol treatment to replace it with a capsule without speaking to the clinician who manages your cardiovascular risk. ANSES — contraindications and populations concerned

• Immediately stop using an officially recalled product.
• Keep the name, manufacturer, batch, packaging, and proof of purchase.
• Seek medical advice for any symptom or abnormality.
• Disclose every medication and other supplement.
• Never change prescribed treatment on your own.

10. A more robust method than “laboratory tested”

A badge does not reveal what was tested, which batch was sampled, when the test occurred, which method was used, or who performed it. A heavy-metal analysis does not automatically say anything about a microbial toxin or the actual amount of monacolin K.

First ask what problem the product is meant to solve and why it should come before a food-based or medical solution. Then examine the active substance, amount, interactions, traceability, analysis documents, and stopping rule. If even one answer remains opaque, choosing not to use the product is rational.

Avoid introducing several supplements at once. A stack makes duplicate ingredients, interactions, and adverse effects much harder to attribute. Even the best-controlled product is unnecessary when its expected benefit is neither needed nor measurable.

• A specific need considered in its medical context.
• A known active substance and actual amount.
• Interactions and at-risk populations checked.
• An identifiable manufacturer, batch, and test.
• A stopping criterion defined before use.

11. Nalko tracks the foundations, not cholesterol

Nalko can help you track food, calories, protein, fiber, and the consistency of your habits. That record may reveal that a problem someone hoped to solve with a capsule actually stems from unstructured meals or a plan that is impossible to sustain.

The app does not measure cholesterol, certify supplements, or replace a doctor or pharmacist. Lab tests, treatment, symptoms, and decisions about red yeast rice require professional oversight.

Bottom line

The Kobayashi case should neither taint an entire category by association nor distract from the risks inherent to monacolins. It shows why products at the top of the pyramid demand greater traceability and less trust in the word “natural.”

• Monacolin K can present risks even without contamination.
• Kobayashi experienced a distinct industrial contamination involving P. adametzioides and puberulic acid.
• The administrative order covered three products, not the entire category.
• The record includes a recall, administrative order, investigation, compensation program, and civil lawsuit.
• The official sources consulted do not document any criminal convictions.
• For most people who strength train, this product offers no direct training benefit.